Reports Q1 revenue $88.21M, consensus $86.32M. Joseph Capper, MiMedx (MDXG) CEO, commented, “Our solid first quarter 2025 results include total net sales growth of 4% year-over-year and an Adjusted EBITDA margin of 20%. Our Surgical products recorded double-digit growth during the quarter, and we are continuing to see our efforts to build a compelling body of clinical evidence in this space unlock sizable opportunities for our products.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG:
- MDXG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MiMedx price target lowered to $15 from $16 at Mizuho
- CMS reviewing coverage policies for skin substitute products
- Northland says MiMedx ‘oversold,’ sees ‘compelling buying opportunity’
- MiMedx Group: Strong Sales Performance and Strategic Positioning Support Buy Rating